Etodolac, a new anti-inflammatory, analgesic drug, was evaluated for the treatment of active rheumatoid arthritis in a 12-week double-blind multicenter clinical trial. One hundred ninety-nine patients were randomly assigned to one of three dosage regimens of etodolac, 100 mg q.d., 200 mg q.d., or 100 mg b.i.d.; or sulindac 200 mg b.i.d., or placebo. The 100 mg b.i.d. etodolac dose, established in ... [Show full abstract] another study as the minimum clinically useful regimen, was comparable to sulindac in significantly improving the functional parameters of disease activity. The incidence of patient complaints in the etodolac groups did not differ significantly from the placebo group.